Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 14/20 | 0.49 |
| ▸ | PPARA | Q07869 | 10/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858038 | 0.86 | PPARG (0.53) | KDM4ERAB9ANPC1PPARGPPARA | |
| SCHEMBL5855712 | 0.83 | PPARG (0.55) | KDM4ERAB9ANPC1KDRPPARG | |
| SCHEMBL10202989 | 0.83 | KDM4E (0.60) | KDM4ERAB9ANPC1HPGDKDR | |
| SCHEMBL4037331 | 0.82 | KDM4E (0.69) | KDM4ERAB9ANPC1HPGDKDR | |
| SCHEMBL5857590 | 0.82 | PPARG (0.55) | KDM4ERAB9ANPC1HRH3PPARG | |
| SCHEMBL5857972 | 0.81 | PPARG (0.57) | KDM4ERAB9ANPC1HRH3PPARG | |
| SCHEMBL979145 | 0.80 | KDM4E (0.65) | KDM4ERAB9ANPC1HPGDKDR | |
| SCHEMBL266619 | 0.77 | KDM4E (0.66) | KDM4ERAB9ANPC1HPGDKDR | |
| SCHEMBL4888378 | 0.77 | RAB9A (0.62) | KDM4ERAB9ANPC1HPGDKDR | |
| SCHEMBL5022312 | 0.77 | KDM4E (0.61) | KDM4ERAB9ANPC1HPGDKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | disclosed |
| EP-2567957-A1 | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LIMITED (IN) | 2013-03-13 | — | — | EP | disclosed |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | US | disclosed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | PCSK9, APOB, CPT1A | KDM4E 3925/4885RAB9A 2860/4885NPC1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.